Assistant Professor of Medicine
Division of Clinical Immunology & Rheumatology
Faculty Office Tower, room 850
510 20th Street South
Telephone: (205) 996-9640
BS (Biology), University of Puerto Rico-Mayaguez-Campus, Mayaguez, Puerto Rico, 2001
MD, Universidad Autónoma de Guadalajara School of Medicine, Guadalajara, Jalisco, Mexico, 2005
Residency (Internal Medicine), Baptist Health System, Birmingham, Alabama, 2008-2009
Residency (Internal Medicine), Carraway Methodist Medical Center, Birmingham, Alabama, 2006-2008
Clinical Fellowship (Rheumatology), University of Alabama at Birmingham, Birmingham, Alabama, 2009-2011
Postdoctoral Fellowship, Outcomes and Comparative Effectiveness, University of Alabama at Birmingham, 2010-2012
Research and Clinical Interests
Dr. Navarro-Millán’s area of interest is epidemiology and comparative effectiveness in rheumatic diseases, especially in patients with rheumatoid arthritis. Dr. Navarro-Millán has ongoing projects that include evaluating various aspects of the prevalence, risk factors, and durability of remission in RA using the new American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) remission. Dr. Navarro-Millán is also interested in determining the role of traditional cardiovascular risk factors in coronary heart disease outcomes in patients with rheumatoid arthritis.
Another area of interest for her is to understand the relationship between the clinical and molecular factors that influence the development of complex diseases such as rheumatoid arthritis and other rheumatic diseases and develop prediction models for disease outcomes in RA and other rheumatic diseases using clinical data.
Navarro-Millán I, Singh JA, Curtis JR: Tocilizumab for Rheumatoid Arthritis: A New Biologic Targeting the Interleukin-6 Receptor. Clnl Ther 2012 Apr;34(4):788-802.e3
Curtis JR, Yang S, Chen L, Park GS, Bitman B, Wang B, Navarro-Millán I, Kavanaugh A. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2011 Oct 13. PMID: 21998118.
Curtis JR, Chen L, Luijtens K, Navarro-Millán I, Goel N, Gervitz L, Weinblatt M: Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. Arthritis Rheum. 2011 Aug;63(8):2203-8. PMID: 21484766.
Costenbader KH, Khamashta M, Ruiz-Garcia S, Perez-Rodriguez MT, Petri M, Elliott J, Manzi S, Karlson EW, Turner-Stokes T, Bermas B, Coblyn J, Massarotti E, Schur P, Fraser P, Navarro I, Hanly JG, Shaver TS, Katz RS, Chakravarty E, Fortin PR, Sanchez ML, Liu J, Michaud K, Alarcón GS, Wolfe F: Development and initial validation of a self-assessed lupus organ damage instrument. Arthritis Care Res. 2010 Apr;62(4):559-68. PMCID: PMC 3179258.
Pons-Estel BA, Sánchez-Guerrero J, Romero-Díaz J, Iglesias-Gamarra A, Bonfa E, Borba EF, Shinjo SK, Bernatsky S, Clarke A, García MA, Marcos JC, Duarte A, Berbotto GA, Scherbarth H, Marques CD, Onetti L, Saurit V, Souza AW, Velozo E, Catoggio LJ, Neira O, Burgos PI, Ramirez LA, Molina JF, De La Torre IG, Silvariño R, Manni JA, Durán-Barragán S, Vilá LM, Fortin PR, Calvo-Alén J, Santos MJ, Portela M, Esteva-Spinetti MH, Weisman M, Acevedo EM, Segami MI, Gentiletti SB, Roldán J, Navarro I, Gonzalez E, Liu JM, Karlson EW, Costenbader KH, Wolfe F, Alarcón GS: Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and Portugal. Lupus. 2009 Oct;18(12):1033-52. PMCID: PMC2933049.